Get notified when SLS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Going Concern (new) — Company disclosed substantial doubt about ability to continue as going concern due to insufficient cash for next 12 months.
NASDAQ: SLS SELLAS Life Sciences Group, Inc. 10-Q

net income -$8.4M. SELLAS nears REGAL trial readout (78 of 80 events) but discloses going concern warning

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~1 min read

Key Changes

  • high

    Company disclosed substantial doubt about ability to continue as going concern, stating $28.4M cash insufficient for 12-month operations. No new financing announced to address shortfall.

    MD&A: Liquidity verify on EDGAR →
  • high

    REGAL trial reached 78 of 80 required events as of May 11, 2026, signaling final analysis imminent. Company remains blinded to efficacy data; no statistical penalty incurred from one-time event count disclosure.

    MD&A: Clinical Development verify on EDGAR →
  • high

    No milestone payments received in past 12+ months despite ongoing dispute.

    Legal Proceedings verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SAIC 10-Q) is open in full — no account needed.

Partner

Trade SLS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify